HSCI researchers discover on-off switch for gene expression

NewsGuard 100/100 Score

Genes protect themselves against being silenced

Harvard Stem Cell Institute (HSCI) researchers have settled a century-old debate over whether occurrence of DNA methylation acts to silence gene expression, or if genes are turned off by other means before they are methylated.

As explicated today in the journal Nature, methylation in fact enforces gene silencing, and it is levels of a newly identified form of RNA produced by individual genes that determines whether they are turned off by the addition of a methyl (CH3) group by the enzyme DNA methylase 1 (DNMT1).

The study, led by HSCI Principal Faculty member Daniel Tenen, MD, found that during transcription of DNA to RNA, a gene produces a small amount of what the investigators named "extracoding RNA," which stays in the nucleus and binds to DNMT1, blocking its ability to methylate, or silence the gene. The discovery of RNA's new function has therapeutic potential as an on-off switch for gene expression.

"We have demonstrated, at least for one gene in detail, and probably thousands more, that extracoding RNA serves to protect the gene from methylation," said Tenen, who heads laboratories at Beth Israel Deaconess Medical Center and the Cancer Science Institute of Singapore, where he is director, at the National University of Singapore. "When the RNA is shut off, which we did by various means, the gene becomes methylated."

Postdoctoral fellow Annalisa Di Ruscio, MD, PhD, and laboratory staff member Alexander Ebralidze, PhD, were major contributors to the work.

The biological irony is that DNMT1 has long been considered a DNA-binding enzyme, so it is surprising that it is able to bind so well to extracoding RNA, Tenen explained.

"If you put extracoding RNA into a cell, you can actually inhibit the ability of DNMT1 to maintain methylation patterns of that gene and induce demethylation in a gene-selective manner," Tenen said. "The reason this is interesting is the cancers and other disease are treated using demethylation agents, so this gives us the opportunity to try to direct gene-specific demethylation."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles